Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Replimune Group, Inc. alleging that the company made false and misleading statements regarding its FDA submission for RP1-104. The complaint claims Replimune failed to disclose study design concerns from the FDA and submitted data from an early analysis with only 40 patients instead of the planned 400, which likely caused FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 are eligible to join the case.